AU Patent

AU2024247020A1 — Dosing schedule of a her2 inhibitor

Assigned to Boehringer Ingelheim International GmbH · Expires 2025-10-30 · 1y expired

What this patent protects

The present invention relates to a dosing schedule of a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular to its doses and second or further line administration.

USPTO Abstract

The present invention relates to a dosing schedule of a HER2 inhibitor useful in the prevention and/or treatment of cancer, in particular to its doses and second or further line administration.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024247020A1
Jurisdiction
AU
Classification
—
Expires
2025-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.